Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 257 articles:
HTML format



Single Articles


    May 2020
  1. MOHAMADI M, Azarbayjani K, Mozhgani SH, Bamdad T, et al
    Hepatitis C virus alternative reading frame protein (ARFP): production, features and pathogenesis.
    J Med Virol. 2020 May 29. doi: 10.1002/jmv.26091.
    PubMed     Abstract available


  2. LIU Y, Zhao ZH, Lv XQ, Tang YW, et al
    Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models.
    J Med Virol. 2020 May 19. doi: 10.1002/jmv.26025.
    PubMed     Abstract available


  3. WAHID B, Shami K, Joiya SA, Ozuyar SEG, et al
    Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    J Med Virol. 2020 May 17. doi: 10.1002/jmv.25931.
    PubMed     Abstract available


  4. ODJIDJA EN, Longo VL, Rizzatti G, Bandoh S, et al
    Coronavirus Disease 2019 and Viral Hepatitis coinfection: Provide guidelines for integrated screening and treatment.
    J Med Virol. 2020 May 15. doi: 10.1002/jmv.26021.
    PubMed     Abstract available


  5. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25984.
    PubMed     Abstract available


  6. AMSTUTZ A, Nsakala BL, Cheleboi M, Lejone TI, et al
    Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: a multicenter screening study in Lesotho.
    J Med Virol. 2020 May 5. doi: 10.1002/jmv.25970.
    PubMed     Abstract available


    April 2020
  7. KOC OM, Robaeys G, Topal H, Bielen R, et al
    Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.
    J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25950.
    PubMed     Abstract available


  8. JAMIL Z, Waheed Y, Ahsan O, Najmi MH, et al
    Familial Clustering of Hepatitis C Virus in Pakistani Population.
    J Med Virol. 2020 Apr 22. doi: 10.1002/jmv.25926.
    PubMed     Abstract available


  9. KODANI M, Poe A, Drobeniuc J, Hayden T, et al
    Determination of potential biotin interference on accuracy of results of serologic assays for various viral hepatitis markers.
    J Med Virol. 2020 Apr 14. doi: 10.1002/jmv.25880.
    PubMed     Abstract available


  10. AVELLON A, Ala A, Diaz A, Domingo D, et al
    Clinical Performance of Determine(TM) HBsAg 2 rapid test for hepatitis B detection.
    J Med Virol. 2020 Apr 9. doi: 10.1002/jmv.25862.
    PubMed     Abstract available


    March 2020
  11. JAMSHIDI S, Bokharaei-Salim F, Esghaei M, Bastani MN, et al
    Occult HCV and Occult HBV Co-infection in Iranian Human Immunodeficiency Virus-Infected Individuals.
    J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25808.
    PubMed     Abstract available


  12. BAI X, Ma X, Li M, Li X, et al
    Field applicable detection of hepatitis B virus using internal controlled duplex recombinase-aided amplification assay and lateral flow dipstick assay.
    J Med Virol. 2020 Mar 19. doi: 10.1002/jmv.25778.
    PubMed     Abstract available


  13. MARGUSINO-FRAMINAN L, Perez EB, Cid-Silva P, Rodriguez-Sotelo A, et al
    Effectiveness and Safety of Direct-Acting Antivirals in Hepatitis C Infected Patients with Mental Disorders: Results in Real Clinical Practice.
    J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25772.
    PubMed     Abstract available


  14. WANG X, Pan Y, Chen J, Luo J, et al
    The excretion rate and stability of HAAg in human fecal samples after live attenuated hepatitis A vaccination.
    J Med Virol. 2020 Mar 5. doi: 10.1002/jmv.25747.
    PubMed     Abstract available


  15. MUSHTAQ S, Mansoor A, Umar M, Khan A, et al
    Direct-acting antiviral agents in the treatment of chronic Hepatitis C - Real-life experience from clinical practices in Pakistan.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25745.
    PubMed     Abstract available


  16. MEI X, Dai F, Zou J, Zhang H, et al
    Quasispecies dynamics of a hepatitis E virus 4 from the feces and liver biopsy of an acute hepatitis E patient during virus clearance.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25746.
    PubMed     Abstract available


    February 2020
  17. RAHEEL M, Choga WT, Blackard JT
    The distribution of hepatitis B virus surface antigen polymorphisms at positions associated with vaccine escape.
    J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25730.
    PubMed     Abstract available


  18. LIU L, Zhu J, Yang J, Li X, et al
    GP73 Facilitates Hepatitis B Virus Replication by Repressing the NF-kappaB Signaling Pathway.
    J Med Virol. 2020 Feb 20. doi: 10.1002/jmv.25718.
    PubMed     Abstract available


  19. LU C, Feng Y, Sun X, Li N, et al
    Tree Shrew Bone Marrow-Derived Mesenchymal Stem Cells Express CD81, OCLN, and miR-122, Facilitating the Entire Hepatitis C Virus Life Cycle.
    J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25710.
    PubMed     Abstract available


  20. BURA M, Lagiedo-Zelazowska M, Michalak M, Mozer-Lisewska I, et al
    Exposure to hepatitis E virus (HEV) in hemodialysis patients from west-central Poland.
    J Med Virol. 2020 Feb 4. doi: 10.1002/jmv.25696.
    PubMed     Abstract available


  21. DE OLIVEIRA TM, Vieira NSG, Sepp TDS, Souto FJD, et al
    Recent Trends in Hepatitis a Incidence in Brazil.
    J Med Virol. 2020 Feb 3. doi: 10.1002/jmv.25694.
    PubMed     Abstract available


    January 2020
  22. TAMAKI N, Kurosaki M, Nakanishi H, Itakura J, et al
    Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
    J Med Virol. 2020 Jan 29. doi: 10.1002/jmv.25692.
    PubMed     Abstract available


    December 2019
  23. FUCHS M, Monto A, Brau N, Charafeddine M, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.
    J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655.
    PubMed     Abstract available


  24. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    PubMed     Abstract available


    November 2019
  25. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2019 Nov 28. doi: 10.1002/jmv.25644.
    PubMed     Abstract available


  26. OMRAN NM, El-Sherbini SM, Hegazy O, Elshaarawy AA, et al
    Crosstalk between miR-215 and Epithelial-Mesenchymal Transition (EMT) specific markers (E- and N-cadherin) in different stages of chronic HCV Infection.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25637.
    PubMed     Abstract available


  27. JIANG Q, Mao R, Wu J, Chang L, et al
    Platelet Activation During Chronic Hepatitis B Infection Exacerbates Liver Inflammation and Promotes Fibrosis.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25641.
    PubMed     Abstract available


  28. DEL-RIOS NHA, de Araujo LA, Martins RMB, Guimaraes RA, et al
    Molecular and Epidemiological Aspects of Hepatitis C Virus Infection Among Crack Cocaine Users.
    J Med Virol. 2019 Nov 20. doi: 10.1002/jmv.25632.
    PubMed     Abstract available


  29. RODRIGUEZ-TAJES S, Perpinan E, Leonel T, Lens S, et al
    Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak.
    J Med Virol. 2019 Nov 19. doi: 10.1002/jmv.25630.
    PubMed     Abstract available


  30. LI N, Fan X, Wang X, Zhang X, et al
    Genetic association of polymorphisms at intergenic region between PRDM1 and ATG5 with hepatitis B virus infection in Han Chinese patients.
    J Med Virol. 2019 Nov 15. doi: 10.1002/jmv.25629.
    PubMed     Abstract available


  31. SHEN S, Lai-Hung Wong G, Kuang Z, van Campenhout MJH, et al
    Development and validation of a model for hepatitis B e Antigen seroconversion in entecavir-treated chronic hepatitis B patients.
    J Med Virol. 2019 Nov 14. doi: 10.1002/jmv.25628.
    PubMed     Abstract available


  32. HUANG J, Jing M, Wang C, Wang M, et al
    The impact of hepatitis B virus infection status on the prevalence of non-alcoholic fatty liver disease: A population-based study.
    J Med Virol. 2019 Nov 6. doi: 10.1002/jmv.25621.
    PubMed     Abstract available


    October 2019
  33. GRABARCZYK P, Kubicka-Russel D, Kopacz A, Liszewski G, et al
    Seronegative hepatitis C virus (HCV) infection in Polish blood donors - virological characteristics of index donations and follow-up observations.
    J Med Virol. 2019 Oct 31. doi: 10.1002/jmv.25617.
    PubMed     Abstract available


  34. MAHMUD S, Chemaitelly HS, Kouyoumjian SP, Kanaani ZA, et al
    Key associations for hepatitis C virus genotypes in the Middle East and North Africa.
    J Med Virol. 2019 Oct 30. doi: 10.1002/jmv.25614.
    PubMed     Abstract available


  35. GU Y, Chen L, Lian Y, Gu L, et al
    Serum HBV Pregenomic RNA Is Correlated with Th1/Th2 Immunity in Treatment-Naive Chronic Hepatitis B Patients.
    J Med Virol. 2019 Oct 23. doi: 10.1002/jmv.25612.
    PubMed     Abstract available


  36. KOC OM, Menart C, Theodore J, Kremer C, et al
    Ethnicity and response to primary three-dose hepatitis B vaccination in employees in the Netherlands, 1983 through 2017.
    J Med Virol. 2019 Oct 17. doi: 10.1002/jmv.25610.
    PubMed     Abstract available


  37. WANG YH, Liao J, Zhang DM, Wu DB, et al
    Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    J Med Virol. 2019 Oct 14. doi: 10.1002/jmv.25608.
    PubMed     Abstract available


  38. TSAI TC, Deng ST, Hsu CW
    The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    J Med Virol. 2019 Oct 10. doi: 10.1002/jmv.25605.
    PubMed     Abstract available


  39. SAITO Y, Imamura M, Uchida T, Osawa M, et al
    Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602.
    PubMed     Abstract available


  40. SAMPEDRO A, Casanovas I, Ceballos J, Rodriguez-Granger J, et al
    Comparative evaluation of two immunoassays for serological diagnosis of hepatitis E.
    J Med Virol. 2019 Oct 3. doi: 10.1002/jmv.25601.
    PubMed     Abstract available


    September 2019
  41. ZHENG B, Zhang J, Zheng T, Wang H, et al
    ATP1B3 Cooperates with BST-2 to Promote Hepatitis B Virus Restriction.
    J Med Virol. 2019 Sep 26. doi: 10.1002/jmv.25599.
    PubMed     Abstract available


  42. ABE H, Ushijima Y, Bikangui R, Loembe MM, et al
    Ongoing evolution of hepatitis B virus during viremia in febrile patients in Central Africa.
    J Med Virol. 2019 Sep 20. doi: 10.1002/jmv.25598.
    PubMed     Abstract available


  43. BIN WAHID S, Ain QU, Quraishi A, Wahid B, et al
    Clinical correlation of liver function tests with suppression of cytokine signaling (SOCS1) gene expression in HCV infected patients: a real-world clinical experience.
    J Med Virol. 2019 Sep 19. doi: 10.1002/jmv.25596.
    PubMed     Abstract available


  44. HAO QQ, Wang QH, Xia W, Qian HZ, et al
    Circulating miRNA Expression Profile and Bioinformatics Analysis in Patients with Occult Hepatitis B Virus Infection.
    J Med Virol. 2019 Sep 12. doi: 10.1002/jmv.25594.
    PubMed     Abstract available


  45. XING M, Feng Y, Yao J, Lv H, et al
    Induction of Peripheral Blood T-follicular Helper Cells Expressing ICOS Correlates with Antibody Response to Hepatitis B Vaccination.
    J Med Virol. 2019 Sep 2. doi: 10.1002/jmv.25585.
    PubMed     Abstract available


    August 2019
  46. CUI H, Jin Y, Chen F, Ni H, et al
    Clinicopathological evidence of Hepatitis B Virus infection in the development of gastric adenocarcinoma.
    J Med Virol. 2019 Aug 31. doi: 10.1002/jmv.25584.
    PubMed     Abstract available


  47. LEE KC, Lin CL, Hsu CW, Chang ML, et al
    Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 - 2019.
    J Med Virol. 2019 Aug 30. doi: 10.1002/jmv.25582.
    PubMed     Abstract available


  48. JANG ES, Kim KA, Kim YS, Kim IH, et al
    Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: an emphasis on the pretreatment NS5A resistance-associated substitution test.
    J Med Virol. 2019 Aug 26. doi: 10.1002/jmv.25575.
    PubMed     Abstract available


  49. XU J, Tao LL, Ma LX
    Efficacy and safety of telbivudine to prevent mother-to-child transmission of hepatitis B virus in middle and late stage pregnancy with high viral loads.
    J Med Virol. 2019 Aug 9. doi: 10.1002/jmv.25566.
    PubMed     Abstract available


  50. GHAZY AA, Osman EM, Rashwan EA, Gaballah AH, et al
    Relation between micro RNA-21, Transforming Growth Factor Beta and response to treatment among Chronic Hepatitis C Patients.
    J Med Virol. 2019 Aug 1. doi: 10.1002/jmv.25559.
    PubMed     Abstract available


    July 2019
  51. WAHID B
    Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patient previously treated for Tuberculosis.
    J Med Virol. 2019 Jul 26. doi: 10.1002/jmv.25557.
    PubMed     Abstract available


  52. LEI Y, Shao J, Zhao F, Li Y, et al
    Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate.
    J Med Virol. 2019 Jul 26. doi: 10.1002/jmv.25554.
    PubMed     Abstract available


  53. MACKEN L, Gelson W, Priest M, Abouda G, et al
    Efficacy of direct acting antivirals: UK real world data from a well characterised predominantly cirrhotic HCV cohort.
    J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552.
    PubMed     Abstract available


  54. ROGERS E, Todd M, Pierson FW, Kenney SP, et al
    CD8(+) lymphocytes but not B lymphocytes are required for protection against chronic hepatitis E virus infection in chickens.
    J Med Virol. 2019 Jul 18. doi: 10.1002/jmv.25548.
    PubMed     Abstract available


  55. MODIYINJI AF, Atsama MA, Monamele CG, Nola M, et al
    Seroprevalence of Hepatitis E virus antibodies in different human populations of Cameroon.
    J Med Virol. 2019 Jul 12. doi: 10.1002/jmv.25545.
    PubMed     Abstract available


  56. IMAI S, Yamana H, Inoue N, Akazawa M, et al
    Validity of administrative database detection of previously-resolved hepatitis B virus in Japan.
    J Med Virol. 2019 Jul 8. doi: 10.1002/jmv.25540.
    PubMed     Abstract available


  57. MARTINEZ AP, Garcia G, Ridruejo E, Culasso AC, et al
    Hepatitis C Virus Genotype 1 Infection: Prevalence of NS5A and NS5B Resistance-Associated Substitutions in Naive Patients from Argentina.
    J Med Virol. 2019 Jul 5. doi: 10.1002/jmv.25536.
    PubMed     Abstract available


    June 2019
  58. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25533.
    PubMed     Abstract available


  59. HUANG J, Xu R, Wang M, Liao Q, et al
    Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25531.
    PubMed     Abstract available


  60. TONG S, Pan J, Tang J
    Study on the structure optimization and anti-hepatitis B virus activity of novel human La protein inhibitor HBSC11.
    J Med Virol. 2019 Jun 26. doi: 10.1002/jmv.25528.
    PubMed     Abstract available


  61. CHEN Y, Kong Y, Shi L, Zhang X, et al
    Study of the Distribution of Hepatitis B Immunoglobulin in Pregnant Mice Using Small-Animal Imaging Technology.
    J Med Virol. 2019 Jun 17. doi: 10.1002/jmv.25521.
    PubMed     Abstract available


  62. HAGIWARA S, Nishida N, Ida H, Ueshima K, et al
    Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B.
    J Med Virol. 2019 Jun 14. doi: 10.1002/jmv.25515.
    PubMed     Abstract available


  63. MSOMI N, Ndlovu K, Giandhari J, Wilkinson E, et al
    High rate of occult hepatitis B virus infection in haemodialysis units of KwaZulu-Natal, South Africa.
    J Med Virol. 2019 Jun 10. doi: 10.1002/jmv.25510.
    PubMed     Abstract available


  64. MELO DA SILVA E, Kay A, Lobato C, Muwonge R, et al
    Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.
    J Med Virol. 2019;91:1081-1086.
    PubMed     Abstract available


  65. KHANIZADEH S, Hasanvand B, Nikoo HR, Anbari K, et al
    Association between miRNA-146a rs2910164 (G/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population.
    J Med Virol. 2019;91:1063-1068.
    PubMed     Abstract available


    May 2019
  66. IFEORAH IM, Faleye TOC, Bakarey AS, Adewumi OM, et al
    Characterization of Hepatitis Delta Virus strains spreading in Abuja, Nigeria.
    J Med Virol. 2019 May 13. doi: 10.1002/jmv.25503.
    PubMed     Abstract available


  67. SLAVOV SN, de Matos Maconetto J, Martinez EZ, Silva-Pinto AC, et al
    PREVALENCE OF HEPATITIS E VIRUS INFECTION IN MULTIPLE TRANSFUSED BRAZILIAN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE.
    J Med Virol. 2019 May 8. doi: 10.1002/jmv.25498.
    PubMed     Abstract available


    April 2019
  68. DING X, Lei Q, Li T, Li L, et al
    Hepatitis B core antigen can regulate NLRP3 inflammasome pathway in HepG2 cells.
    J Med Virol. 2019 Apr 24. doi: 10.1002/jmv.25490.
    PubMed     Abstract available


  69. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2019 Apr 12. doi: 10.1002/jmv.25485.
    PubMed     Abstract available


  70. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


  71. ZAYED SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, et al
    Genetic variations in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
    J Med Virol. 2019 Apr 4. doi: 10.1002/jmv.25476.
    PubMed     Abstract available


    March 2019
  72. BARUAH V, Bose S
    Computational identification of Hepatitis-E virus encoded microRNAs and their targets in human.
    J Med Virol. 2019 Mar 28. doi: 10.1002/jmv.25471.
    PubMed     Abstract available


  73. JAVANMARD D, Namaei MH, Farahmand M, Ziaee A, et al
    Molecular and serological characterization of occult hepatitis B virus infection among patients with hemophilia.
    J Med Virol. 2019 Mar 25. doi: 10.1002/jmv.25470.
    PubMed     Abstract available


  74. LIU T, Sun Y, Zhou J, Yang F, et al
    On-treatment changes of serum wisteria floribunda agglutinin-positive mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon alpha add-on therapy.
    J Med Virol. 2019 Mar 24. doi: 10.1002/jmv.25465.
    PubMed     Abstract available


  75. WANG X, Chen Q, Li H, Wang C, et al
    Asymptomatic hepatitis B carriers who were vaccinated at birth.
    J Med Virol. 2019 Mar 18. doi: 10.1002/jmv.25461.
    PubMed     Abstract available


  76. KOC OM, Kremer C, Bielen R, Buscchots D, et al
    Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: importance of migration.
    J Med Virol. 2019 Mar 14. doi: 10.1002/jmv.25457.
    PubMed     Abstract available


  77. HUANG R, Rao H, Xie Q, Gao Z, et al
    Comparison of Efficacy of Sofosbuvir plus Ribavirin in Chinese Patients with Genotype 3a or 3b HCV Infection.
    J Med Virol. 2019 Mar 12. doi: 10.1002/jmv.25454.
    PubMed     Abstract available


  78. SI J, Li J, Zhang L, Zhang W, et al
    A signal amplification system on a lateral flow immunoassay detecting for hepatitis e antigen in human blood samples.
    J Med Virol. 2019 Mar 9. doi: 10.1002/jmv.25452.
    PubMed     Abstract available


  79. POORDAD F, Bennett M, Sepe TE, Cohen E, et al
    Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with HCV genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    J Med Virol. 2019 Mar 6. doi: 10.1002/jmv.25448.
    PubMed     Abstract available


    February 2019
  80. HSU CW, Yeh C, Yeh CT
    Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in chronic hepatitis B patients.
    J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25443.
    PubMed     Abstract available


  81. IIDA-UENO A, Enomoto M, Kozuka R, Tamori A, et al
    Switching to tenofovir disoproxil fumarate versus continuing treatment in chronic hepatitis B patients who maintain long-term virological response to entecavir therapy: a randomized trial.
    J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25442.
    PubMed     Abstract available


  82. BOGLIONE L, Lupia T, Cariti G, Ghisetti V, et al
    Antiviral treatment with PEG-IFN and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: a retrospective analysis.
    J Med Virol. 2019 Feb 22. doi: 10.1002/jmv.25438.
    PubMed     Abstract available


  83. WANG W, Zhao X, Li G, Wang L, et al
    Diagnostic Thresholds and Performance of Non-invasive Fibrosis Scores are Limited by Age in Patients with Chronic Hepatitis B.
    J Med Virol. 2019 Feb 20. doi: 10.1002/jmv.25435.
    PubMed     Abstract available


  84. WEI MT, Le AK, Chang MS, Hsu H, et al
    Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
    J Med Virol. 2019 Feb 18. doi: 10.1002/jmv.25433.
    PubMed     Abstract available


  85. HUANG Y, Wang B, Peng Z, Tang N, et al
    Hepatitis B virus Surface gene mutants in immunoprophylaxis-failed infants from Southern China.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25430.
    PubMed     Abstract available


  86. BARFI S, Poortahmasebi V, Ofoghi H, Farahmand M, et al
    Measurement of serum hepatitis B surface antibody (HBs-Ab) levels in Iranian autistic children and evaluation of immunological memory after booster dose injection in comparison with controls.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25429.
    PubMed     Abstract available


  87. HETTA HF, Zahran AM, Mansor SG, Abdel-Malek MO, et al
    Frequency and Implications of Myeloid Derived Suppressor Cells and Lymphocyte Subsets in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25428.
    PubMed     Abstract available


  88. SONG C, Shan Z, Kang F, Li W, et al
    A 3-year-long investigation of the authenticity of the return results of hepatitis B virus qualitative testing in external quality assessment in East China.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25431.
    PubMed     Abstract available


  89. GHASEMI A, Zadsar M, Shaiegan M, Samiei S, et al
    Human platelet antigens polymorphisms; Association to the development of liver fibrosis in patients with chronic hepatitis C.
    J Med Virol. 2019 Feb 6. doi: 10.1002/jmv.25423.
    PubMed     Abstract available


  90. LIU C, Wu W, Shang S, Huang E, et al
    Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    J Med Virol. 2019;91:249-257.
    PubMed     Abstract available


    January 2019
  91. KWON JH, Yoo SH, Nam SW, Kim HY, et al
    Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea.
    J Med Virol. 2019 Jan 29. doi: 10.1002/jmv.25412.
    PubMed     Abstract available


  92. KWEON OJ, Lim YK, Kim HR, Kim TH, et al
    Analytical Performance of Newly Developed Rapid Point-of-Care Test for the Simultaneous Detection of Hepatitis A, B, and C Viruses in Serum Samples.
    J Med Virol. 2019 Jan 22. doi: 10.1002/jmv.25405.
    PubMed     Abstract available


  93. JUNIASTUTI, Wahyuddin D, Nihayatussa'adah, Amin M, et al
    ANALYSIS OF GENETIC AND SEROLOGY OF HEPATITIS A VIRUS INFECTION DURING AND AFTER OUTBREAK IN TWO JUNIOR HIGH SCHOOLS IN SURABAYA, INDONESIA.
    J Med Virol. 2019 Jan 19. doi: 10.1002/jmv.25403.
    PubMed     Abstract available


  94. ZHU XB, Zhuo LY, Yue M, Liu M, et al
    Genetic variants in IFIH1 and DDX58 influence HCV clearance in Chinese Han Population.
    J Med Virol. 2019 Jan 11. doi: 10.1002/jmv.25398.
    PubMed     Abstract available


    December 2018
  95. BAVARO DF, Saracino A, Fiordelisi D, Bruno G, et al
    Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV co-infected individuals.
    J Med Virol. 2018 Dec 22. doi: 10.1002/jmv.25385.
    PubMed     Abstract available


  96. TORRES MC, Civetta E, D'amico C, Barbini L, et al
    Hepatitis B virus in Mar del Plata, Argentina: Genomic characterization and evolutionary analysis of subgenotype F1b.
    J Med Virol. 2018 Dec 20. doi: 10.1002/jmv.25383.
    PubMed     Abstract available


  97. YOSRY A, Gamal Eldeen H, Medhat E, Mehrez M, et al
    Ef fi cacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
    J Med Virol. 2018 Dec 14. doi: 10.1002/jmv.25362.
    PubMed     Abstract available


  98. LIU Y, Wang G, Chen Y, Huang R, et al
    HBcAg-induced up-regulated 4-1BB ligand on B cells contributes to B cell hyperactivation during chronic hepatitis B infection.
    J Med Virol. 2018 Dec 14. doi: 10.1002/jmv.25377.
    PubMed     Abstract available


  99. LIAO Y, Gong J, Zhou W, Dong H, et al
    Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase.
    J Med Virol. 2018 Dec 10. doi: 10.1002/jmv.25364.
    PubMed     Abstract available


  100. BEN S, Yan WJ, Xia W, Juan FJ, et al
    VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
    J Med Virol. 2018 Dec 5. doi: 10.1002/jmv.25373.
    PubMed     Abstract available


  101. SINGH L, Bell TG, Yousif M, Kramvis A, et al
    Response of hepatitis B virus to anti-retroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25375.
    PubMed     Abstract available


  102. COSTA JEF, Morais VMS, Goncales JP, Medeiros AADP, et al
    Occult Hepatitis B Virus Infection in Patients with Leprosy.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25374.
    PubMed     Abstract available


    November 2018
  103. TRIPATHY AS, Puranik S, Sharma M, Chakraborty S, et al
    Hepatitis E Virus Seroprevalence among Blood Donors in Pune, India.
    J Med Virol. 2018 Nov 29. doi: 10.1002/jmv.25370.
    PubMed     Abstract available


  104. MALAGNINO V, Bottero J, Miailhes P, Lascoux-Combe C, et al
    Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25360.
    PubMed     Abstract available


  105. KHAN AJ, Saraswat VA, Ranjan P, Parmar D, et al
    Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25359.
    PubMed     Abstract available


  106. KOC OM, Robaeys G, Yildirim B, Posthouwer D, et al
    The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25353.
    PubMed     Abstract available


  107. NAGAOKI Y, Imamura M, Nisihda Y, Daijo K, et al
    The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25352.
    PubMed     Abstract available


  108. DA COSTA MARQUES BORGES LF, Zalis MG, Santoro-Lopes G, Varella RB, et al
    Hepatitis C virus (HCV) genotypes in hemodialysis patients in Angola.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25354.
    PubMed     Abstract available


    October 2018
  109. HOLZMAYER V, Hance R, Defechereux P, Grant R, et al
    Identification of Hepatitis B virus genotype I in Thailand.
    J Med Virol. 2018 Oct 23. doi: 10.1002/jmv.25346.
    PubMed     Abstract available


  110. AZARKAR Z, Ziaee M, Ebrahimzadeh A, Sharifzadeh G, et al
    Epidemiology, risk factors and molecular characterization of occult hepatitis B infection among anti-HBc alone subjects.
    J Med Virol. 2018 Oct 21. doi: 10.1002/jmv.25343.
    PubMed     Abstract available


  111. YUGO DM, Cossaboom CM, Heffron CL, Huang YW, et al
    Evidence for an Unknown Agent Antigenically Related to the Hepatitis E Virus in Dairy Cows in the United States.
    J Med Virol. 2018 Oct 14. doi: 10.1002/jmv.25339.
    PubMed     Abstract available


  112. YANG H, Wu J, Yuan Y, Huang W, et al
    Retrospectively Seroprevalence Study on Anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital.
    J Med Virol. 2018 Oct 11. doi: 10.1002/jmv.25335.
    PubMed     Abstract available


    September 2018
  113. EL HADI H, Benani A, Qmichou Z, Lazar F, et al
    Development and Validation of an RT-qPCR Assay for Rapid Detection and Quantification of Hepatitis C Virus RNA for Routine Testing in Moroccan Clinical Specimens.
    J Med Virol. 2018 Sep 29. doi: 10.1002/jmv.25326.
    PubMed     Abstract available


  114. WAHID B, Waqar M, Rasool N, Wasim M, et al
    Prevalence of TSH dysfunction among sofosbuvir-treated HCV infected patients: a real-world clinical experience.
    J Med Virol. 2018 Sep 19. doi: 10.1002/jmv.25319.
    PubMed     Abstract available


  115. PENG H, Zhang L, Feng Y, Tang H, et al
    A cross-sectional serum investigation of a clustering HCV infection in Southwest China.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25315.
    PubMed     Abstract available


  116. KHOSRAVI A, Karimi-Sari H, Abedi-Andani M, Behnava B, et al
    Acute Changes in Cardiac Function by Direct-acting Antiviral Therapy for Hepatitis C Infected Thalassemia Patients.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25314.
    PubMed     Abstract available


  117. GUOPING D, Xiaoshan L, Musa TH, Yu J, et al
    The Nationwide Distribution and Trends of Hepatitis C Virus Genotypes in Mainland China.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25311.
    PubMed     Abstract available


  118. SASAKI R, Meyer K, Moriyama M, Kato N, et al
    Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25310.
    PubMed     Abstract available


  119. LI Y, Zeng Y, Zeng G, Li J, et al
    The Effects of Direct-Acting Antiviral Agents on the Frequency of Myeloid-Derived Suppressor Cells and Natural Killer Cells in Patients with Chronic Hepatitis C.
    J Med Virol. 2018 Sep 1. doi: 10.1002/jmv.25302.
    PubMed     Abstract available


    August 2018
  120. CANGIN C, Focht B, Harris R, Strunk JA, et al
    Hepatitis E Seroprevalence in the United States: Results for Immunoglobulins IgG and IgM.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25299.
    PubMed     Abstract available


  121. TANG X, Yan L, Li H, Du L, et al
    Increased Expression of Phosphoenolpyruvate Carboxykinase Cytoplasmic Isoform by Hepatitis B Virus X Protein Affects HBV Replication.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25300.
    PubMed     Abstract available


  122. GOURARI S, Brichler S, Le Gal F, Abdou-Chekaraou SM, et al
    Hepatitis B Virus and Hepatitis Delta Virus (HDV) Subtypes Circulating in Algeria and Seroprevalence of HDV Infection.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25301.
    PubMed     Abstract available


  123. CELLA E, Golgochvea-Markova E, Sagnelli C, Scolamacchia V, et al
    Human hepatitis E virus circulation in Bulgaria: deep Bayesian phylogenetic analysis for viral spread control in the country.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25296.
    PubMed     Abstract available


  124. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Abstract available


  125. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Abstract available


  126. CASTRO VOL, Tejada-Strop A, Weis SMS, Stabile AC, et al
    Evidence of hepatitis E virus infections among persons who use crack cocaine from the Midwest region of Brazil.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25288.
    PubMed     Abstract available


  127. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Abstract available


  128. JIN J, Xu H, Wu R, Niu J, et al
    Aberrant DNA methylation profile of hepatitis B virus infection.
    J Med Virol. 2018 Aug 17. doi: 10.1002/jmv.25284.
    PubMed     Abstract available


  129. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25278.
    PubMed     Abstract available


  130. KAHYESH-ESFANDIARY R, Sadigh ZA, Esghaei M, Bastani MN, et al
    Detection of HCV Genome in Peripheral Blood Mononuclear Cells of Iranian Seropositive and HCV RNA negative in Plasma of Patients with Beta-thalassemia Major: Occult HCV Infection.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25279.
    PubMed     Abstract available


  131. LU T, Han Y, Zhang R, Zhang K, et al
    Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25280.
    PubMed     Abstract available


  132. FLORES GL, Cruz HM, Miguel JC, Potsch DV, et al
    Assessing Hepatitis B immunity using dried blood spot samples from HIV(+) individuals.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25275.
    PubMed     Abstract available


  133. PRAKASH S, Shukla S, Ramakrishna V, Jain A, et al
    Distribution of Hepatitis C Genotypes in Uttar Pradesh, India; Rare Genotype 4 Detected.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25277.
    PubMed     Abstract available


  134. YANG D, Hu T, Wu X, Li K, et al
    Droplet digital polymerase chain reaction for detection of clinical hepatitis B virus DNA samples.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25276.
    PubMed     Abstract available


    July 2018
  135. HARDTKE S, Rocco R, Ogata J, Braga S, et al
    Risk factors and seroprevalence of Hepatitis E evaluated in frozen serum samples (2002-2003) of pregnant women compared to female blood donors in a Southern Region of Brazil.
    J Med Virol. 2018 Jul 31. doi: 10.1002/jmv.25274.
    PubMed     Abstract available


  136. CHIHAB H, Jadid FZ, Foka P, Zaidane I, et al
    PD-1 3'untranslated region polymorphism is associated with spontaneous clearance of Hepatitis B virus infection.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25265.
    PubMed     Abstract available


  137. MORIO K, Imamura M, Kawakami Y, Nakamura Y, et al
    Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25267.
    PubMed     Abstract available


  138. HASHEM M, Zaghla H, Zakaria Z, Allam WR, et al
    High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection.
    J Med Virol. 2018 Jul 16. doi: 10.1002/jmv.25270.
    PubMed     Abstract available


  139. YAMASAKI K, Tanaka J, Kurisu A, Akita T, et al
    Natural course of persistent hepatitis B virus infection in HBe antigen-positive and -negative cohorts in Japan based on the Markov model.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25260.
    PubMed     Abstract available


  140. ZHAO N, Zheng W, Wu D, Wang X, et al
    Clinical value of HCcAg levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25256.
    PubMed     Abstract available


  141. JOGEDA EL, Avi R, Pauskar M, Kallas E, et al
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol. 2018 Jul 10. doi: 10.1002/jmv.25258.
    PubMed     Abstract available


  142. EL BATAE H, Amer I, Kobtan A, Saied SM, et al
    Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt.
    J Med Virol. 2018 Jul 7. doi: 10.1002/jmv.25249.
    PubMed     Abstract available


    June 2018
  143. DEGEFA B, Gebreeyesus T, Gebremedhin Z, Melkamu G, et al
    Prevalence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three year retrospective study.
    J Med Virol. 2018 Jun 15. doi: 10.1002/jmv.25248.
    PubMed     Abstract available


  144. ZHANG W, Huang J, Wang M, Song D, et al
    Characterization of monocytic and granulocytic subsets of myeloid-derived suppressor cells in blood donors with occult hepatitis B virus infection.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25242.
    PubMed     Abstract available


  145. KIM HY, Yoo JJ, Oh S, Yu SJ, et al
    Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25241.
    PubMed     Abstract available


  146. WAKED I, Esmat G, Fouad R, Allam N, et al
    Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE-II study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25243.
    PubMed     Abstract available


    May 2018
  147. CREMER J, Hofstraat SHI, van Heiningen F, Veldhuijzen IK, et al
    Genetic variation of Hepatitis B surface antigen among acute and chronic hepatitis B virus infections in the Netherlands.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25232.
    PubMed     Abstract available


  148. LARSSON SB, Tripodi G, Raimondo G, Saitta C, et al
    Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25227.
    PubMed     Abstract available


  149. MARYAM M, Idrees M
    Study of promoter hypomethylation profiles of RAS oncogenes in Hepatocellular Carcinoma derived from Hepatitis C virus genotype 3a in Pakistani population.
    J Med Virol. 2018 May 9. doi: 10.1002/jmv.25221.
    PubMed     Abstract available


  150. CELLA E, Riva E, Angeletti S, Fogolari M, et al
    Genotype I Hepatitis A virus introduction in Italy: Bayesian phylogenetic analysis to date different epidemics.
    J Med Virol. 2018 May 8. doi: 10.1002/jmv.25220.
    PubMed     Abstract available


  151. CAO D, Ni YY, Walker M, Huang YW, et al
    Roles of the genomic sequence surrounding the stem-loop structure in the junction region including the 3' terminus of ORF1 in hepatitis E virus replication.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25215.
    PubMed     Abstract available


  152. ALEM SA, Said M, Anwar I, Abdellatif Z, et al
    Improvement of LSM, ARFI measurements and non-invasive fibrosis markers after DAAs for HCV G4 recurrence post living donor liver transplantation: Egyptian cohort.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25210.
    PubMed     Abstract available


  153. DE DIEU LONGO J, Bouassa RM, Simaleko MM, Kouabosso A, et al
    Usefulness of simultaneous screening for HIV- and HCV- specific antibodies and HBsAg by capillary-based multiplex rapid diagnostic test to strengthen linkage-to-care in sub-Saharan patients attending sexually transmitted infections clinic.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25209.
    PubMed     Abstract available


  154. BURA M, Michalak M, Lagiedo-Zelazowska M, Bukowska A, et al
    HEV seroprevalence can significantly change after re-assessment.
    J Med Virol. 2018;90:783-785.
    PubMed    


  155. LAI A, Sagnelli C, Presti AL, Cella E, et al
    What is changed in HBV molecular epidemiology in Italy?
    J Med Virol. 2018;90:786-795.
    PubMed     Abstract available


    April 2018
  156. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25197.
    PubMed     Abstract available


  157. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25196.
    PubMed     Abstract available


  158. NIGUSE S, Hailekiros H, Buruh G, Dejene T, et al
    Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women attending antenatal care in health facilities of Tigray, Northern Ethiopia.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25190.
    PubMed     Abstract available


  159. LIU K, Xie M, Lu X, Yu H, et al
    Mutations Within the Major Hydrophilic Region(MHR) of Hepatitis B Virus from individuals with simultaneous HBsAg and anti-HBs in Guangzhou, southern China.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25188.
    PubMed     Abstract available


  160. Z M, H K, E M, N B, et al
    Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About 8 cases resolved by a sequencing method.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25191.
    PubMed     Abstract available


  161. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 14. doi: 10.1002/jmv.25088.
    PubMed     Abstract available


  162. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 12. doi: 10.1002/jmv.25089.
    PubMed     Abstract available


  163. VISCO-COMANDINI U, Lapa D, Lionetti R, Taibi C, et al
    Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25084.
    PubMed     Abstract available


  164. YANG R, Gao N, Chang Q, Meng X, et al
    The role of IDO, IL-10 and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25083.
    PubMed     Abstract available


  165. GONG J, Liang YL, Zhou W, Jie Y, et al
    Prognostic value of neutrophil-to-lymphocyte ratio associated with prognosis in HBV-infected patients.
    J Med Virol. 2018;90:730-735.
    PubMed     Abstract available


  166. MATSUDA H, Hiramatsu K, Akazawa Y, Nosaka T, et al
    Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents.
    J Med Virol. 2018;90:712-720.
    PubMed     Abstract available


  167. CHEN W, Wang L, Niu Y, Ji G, et al
    Distribution of peripheral dendritic cells in patients with HBV infection or spleen and kidney deficiency.
    J Med Virol. 2018;90:706-711.
    PubMed     Abstract available


  168. LI Y, Liu S, Deng Q, Ling L, et al
    A sensitive colorimetric DNA biosensor for specific detection of the HBV gene based on silver-coated glass slide and G-quadruplex-hemin DNAzyme.
    J Med Virol. 2018;90:699-705.
    PubMed     Abstract available


    March 2018
  169. YANG N, Feng J, Zhou T, Li Z, et al
    Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients.
    J Med Virol. 2018 Mar 30. doi: 10.1002/jmv.25080.
    PubMed     Abstract available


  170. MARASCIO N, Pavia G, Romeo I, Talarico C, et al
    Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
    J Med Virol. 2018 Mar 25. doi: 10.1002/jmv.25073.
    PubMed     Abstract available


  171. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Abstract available


  172. ANTONIO UL, Alicia OM, Antonio MJ, Elena GM, et al
    Presence of rare hepatitis C virus subtypes, 2j, 2k and 2r, in Mexico City as identified by sequencing.
    J Med Virol. 2018 Mar 6. doi: 10.1002/jmv.25070.
    PubMed     Abstract available


    February 2018
  173. COLOMBATTO P, Barbera C, Bortolotti F, Maina AM, et al
    HBV Pre-Core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood.
    J Med Virol. 2018 Feb 28. doi: 10.1002/jmv.25068.
    PubMed     Abstract available


  174. LEE GH, Inoue M, Chong RH, Toh J, et al
    Pyrosequencing Method for Sensitive Detection of HBV Drug Resistance Mutations.
    J Med Virol. 2018 Feb 28. doi: 10.1002/jmv.25066.
    PubMed     Abstract available


  175. CORDIE A, Salama A, El-Sharkawy M, El-Nahaas SM, et al
    Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C.
    J Med Virol. 2018 Feb 24. doi: 10.1002/jmv.25064.
    PubMed     Abstract available


  176. SHOUSHA HI, Abdelaziz RA, Azab SM, Khairy M, et al
    Effect of Treatment with Direct Acting Antivirals on Body Mass Index and Hepatic Steatosis in Chronic Hepatitis C.
    J Med Virol. 2018 Feb 22. doi: 10.1002/jmv.25062.
    PubMed     Abstract available


  177. ZHOU S, Ren L, Xia X, Miao Z, et al
    Hepatitis E virus infection in HIV-infected patients: a large cohort study in Yunnan province, China.
    J Med Virol. 2018 Feb 19. doi: 10.1002/jmv.25060.
    PubMed     Abstract available


  178. RAN M, Huang J, Liang H, Jiang J, et al
    Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25053.
    PubMed     Abstract available


  179. DE CASTRO SANT' ANNA C, de Almeida MKC, Ferreira P, de Oliveira RG, et al
    PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25051.
    PubMed     Abstract available


  180. GRECO L, Renteria SCU, Guarneri D, Orlandi A, et al
    HEV and HAV seroprevalence in men that have sex with men (MSM): an update from Milan, Italy.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25052.
    PubMed     Abstract available


  181. MANCINELLI S, Pirillo MF, Liotta G, Andreotti M, et al
    ANTIBODY RESPONSE TO HEPATITIS B VACCINE IN HIV-EXPOSED INFANTS IN MALAWI AND CORRELATION WITH HBV INFECTION ACQUISITION.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25049.
    PubMed     Abstract available


  182. OGATA F, Akuta N, Kobayashi M, Fujiyama S, et al
    Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25047.
    PubMed     Abstract available


  183. GRANDAL M, Pernas B, Tabernilla A, Marino A, et al
    Prevalence of NS5A Resistance Associated Substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on Current Therapeutic Strategies.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25048.
    PubMed     Abstract available


  184. ANASTASIOU OE, Widera M, Korth J, Kefalakes H, et al
    Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA.
    J Med Virol. 2018;90:282-290.
    PubMed     Abstract available


    January 2018
  185. BOGLIONE L, Cariti G, Ghisetti V, Burdino E, et al
    Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis.
    J Med Virol. 2018 Jan 31. doi: 10.1002/jmv.25038.
    PubMed     Abstract available


  186. SUN LJ, Yu JW, Shi YG, Zhang XY, et al
    Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25034.
    PubMed     Abstract available


  187. MOUREZ T, Decroos A, Goria O, Montialoux H, et al
    Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25035.
    PubMed     Abstract available


  188. MARCIANO S, Haddad L, Reggiardo MV, Peralta M, et al
    Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25033.
    PubMed     Abstract available


  189. ALIDJINOU EK, Michel C, Canva V, Ajana F, et al
    Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25028.
    PubMed     Abstract available


  190. MARIO S, Carmine M, Stefania P, Margherita M, et al
    VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25022.
    PubMed     Abstract available


  191. GAMIL M, Alboraie M, El-Sayed M, Elsharkawy A, et al
    Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
    J Med Virol. 2018 Jan 6. doi: 10.1002/jmv.25026.
    PubMed     Abstract available


  192. OHYA K, Akuta N, Suzuki F, Fujiyama S, et al
    Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    J Med Virol. 2018 Jan 5. doi: 10.1002/jmv.25023.
    PubMed     Abstract available


    December 2017
  193. ZHU MY, Chen PZ, Li J, Yu DM, et al
    Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2017 Dec 16. doi: 10.1002/jmv.25010.
    PubMed     Abstract available


  194. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Abstract available


    November 2017
  195. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Abstract available


  196. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Abstract available


    October 2017
  197. KIM DY, Lee HW, Song JE, Kim BK, et al
    Switching from Tenofovir and Nucleoside Analogue Therapy to Tenofovir Monotherapy in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24986.
    PubMed     Abstract available


  198. MEZGEBO TA, Niguse S, Kahsay AG, Hailekiros H, et al
    HEPATITIS B VIRUS INFECTION AND ASSOCIATED RISK FACTORS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN HEALTH FACILITIES OF TIGRAY, NORTHERN ETHIOPIA.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24987.
    PubMed     Abstract available


  199. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Abstract available


  200. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Abstract available


  201. JAVAN B, Reza Kalani M, Shahbazi M
    Interleukin-1 Gene Cluster Haplotype Analysis in the Chronic Outcome Prediction of the Hepatitis B Virus Infection.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24972.
    PubMed     Abstract available


  202. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Abstract available


  203. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Abstract available


  204. AMPONSAH-DACOSTA E, Selabe SG, Mphahlele MJ
    Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.
    J Med Virol. 2017 Oct 2. doi: 10.1002/jmv.24956.
    PubMed     Abstract available


    September 2017
  205. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Abstract available


  206. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Abstract available


  207. ALVARADO-ESQUIVEL C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Alvarado-Felix AO, et al
    Seroepidemiology of hepatitis E virus infection in pigs in Durango State, Mexico.
    J Med Virol. 2017 Sep 15. doi: 10.1002/jmv.24951.
    PubMed     Abstract available


  208. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Abstract available


  209. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Abstract available


  210. SCHULZ TR, Edwards R, Thurnheer MC, Yuen L, et al
    Hepatitis B amongst Immigrants from Myanmar: Genotypes and their Clinical Relevance.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24939.
    PubMed     Abstract available


  211. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Abstract available


  212. ZHANG K, Liu Y, Chen R, Li Q, et al
    Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.
    J Med Virol. 2017 Sep 6. doi: 10.1002/jmv.24936.
    PubMed     Abstract available


    August 2017
  213. MA X, Sun D, Li C, Ying J, et al
    Chronic hepatitis B virus infection and preterm labor(birth) in pregnant women-An updated systematic review and meta-analysis.
    J Med Virol. 2017 Aug 29. doi: 10.1002/jmv.24927.
    PubMed     Abstract available


  214. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Abstract available


  215. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Abstract available


  216. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Abstract available


  217. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Abstract available


  218. ZHAO C, Geng Y, Huang W, Ma H, et al
    Valuable Antibody Detection Method for Classifying Hepatitis E Virus Genotypes.
    J Med Virol. 2017 Aug 17. doi: 10.1002/jmv.24915.
    PubMed     Abstract available


  219. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Abstract available


  220. JOSE-ABREGO A, Panduro A, Fierro NA, Roman S, et al
    High prevalence of HBV infection, detection of subgenotypes F1b, A2 and D4 and differential risk factors among Mexican risk populations with low socioeconomic status.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24913.
    PubMed     Abstract available


  221. TSATSRALT-OD B, Primadharsini PP, Nishizawa T, Ohnishi H, et al
    Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis in Mongolia: The first report of the full genome sequence of a novel genotype 1 hepatitis E virus strain.
    J Med Virol. 2017 Aug 4. doi: 10.1002/jmv.24907.
    PubMed     Abstract available


    July 2017
  222. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Abstract available


  223. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Abstract available


  224. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Abstract available


  225. OSAWA M, Akuta N, Suzuki F, Fujiyama S, et al
    Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.
    J Med Virol. 2017 Jul 1. doi: 10.1002/jmv.24890.
    PubMed     Abstract available


    June 2017
  226. CHEN T, Xun Z, Lin J, Fu Y, et al
    Association between mitochondrial DNA content and baseline serum levels of HBsAg in chronic hepatitis B infection.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24886.
    PubMed     Abstract available


  227. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Abstract available


  228. COSTANTINO A, Coppola N, Spada E, Bruni R, et al
    Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks.
    J Med Virol. 2017 Jun 16. doi: 10.1002/jmv.24880.
    PubMed     Abstract available


  229. ADEYEMI OO, Herod MR, Oladiji F, Fakunle YM, et al
    A multi-template multiplex PCR assay for hepatitis B virus and human beta-globin.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24877.
    PubMed     Abstract available


  230. AHN HS, Park BJ, Han SH, Kim YH, et al
    Prevalence and Genetic Features of Rabbit Hepatitis E Virus in Korea.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24875.
    PubMed     Abstract available


  231. CAI Y, Qin SY, Qian A, Xu P, et al
    Seroprevalence and risk factors of hepatitis E virus infection among the Korean, Manchu, Mongol and Han ethnic groups in eastern and northeastern China.
    J Med Virol. 2017 Jun 3. doi: 10.1002/jmv.24871.
    PubMed     Abstract available


  232. SAGNELLI C, Ciccozzi M, Coppola N, Minichini C, et al
    Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.
    J Med Virol. 2017;89:1015-1024.
    PubMed     Abstract available


  233. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Abstract available


    May 2017
  234. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Abstract available


  235. HUANG X, Ma C, Zhang Q, Shi Q, et al
    Impact of "a" Determinant Mutations on Detection of Hepatitis B Surface Antigen (HBsAg) in HBV Strains from Chinese Patients with Occult Hepatitis B.
    J Med Virol. 2017 May 17. doi: 10.1002/jmv.24859.
    PubMed     Abstract available


  236. DOS SANTOS MIMA, Rugiere SP, Stocker A, Schinoni MI, et al
    Mutations Associated With Drug Resistance and Prevalence of Vaccine Escape Mutations In Patients With Chronic Hepatitis B Infection.
    J Med Virol. 2017 May 13. doi: 10.1002/jmv.24853.
    PubMed     Abstract available


  237. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Abstract available


  238. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Abstract available


  239. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Abstract available


  240. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Abstract available


  241. TRIPODI G, Larsson SB, Norkrans G, Lindh M, et al
    Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24841.
    PubMed     Abstract available


  242. LONG F, Yu W, Yang C, Wang J, et al
    High prevalence of Hepatitis E virus infection in goats.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24843.
    PubMed     Abstract available


    April 2017
  243. SHINDANO TA, Horsmans Y, Kabamba BM
    GENETIC AND PHYLOGENIC CHARACTERISATION OF HEPATITIS B VIRUS IN THE EASTERN PART OF THE DEMOCRATIC REPUBLIC OF CONGO.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24837.
    PubMed     Abstract available


  244. CHAN MC, Cheng FW, Sze KH, Wong AH, et al
    Hepatitis B infection acquired after haematopioetic stem cell transplant through horizontal mode.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24835.
    PubMed     Abstract available


  245. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Abstract available


  246. WANG J, Zhang H, Zhang Y, Jiang D, et al
    Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24830.
    PubMed     Abstract available


  247. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Abstract available


  248. EL-MOWAFY M, Elgaml A, El-Mesery M, Elegezy M, et al
    Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
    J Med Virol. 2017 Apr 8. doi: 10.1002/jmv.24828.
    PubMed     Abstract available


    March 2017
  249. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Abstract available


  250. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Abstract available


  251. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Abstract available


  252. EIJSVOOGEL NB, Hollegien MI, Bok LA, Derksen-Lubsen A, et al
    Declining antibody levels after hepatitis B vaccination in Down syndrome: a need for booster vaccination?
    J Med Virol. 2017 Mar 21. doi: 10.1002/jmv.24813.
    PubMed     Abstract available


  253. CICCOZZI M, Chaouch H, Lo Presti A, Taffon S, et al
    Evolutionary dynamics of HBV-D7 subgenotype in Tunisia.
    J Med Virol. 2017;89:469-475.
    PubMed     Abstract available


  254. ZHANG Y, Wang L, Zeng H, Gong W, et al
    Development and validation of a new serum standard for the measurement of anti-HEV antibodies in animals.
    J Med Virol. 2017;89:497-501.
    PubMed     Abstract available


    September 2016
  255. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Abstract available


  256. JOGEDA EL, Huik K, Pauskar M, Kallas E, et al
    The prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24683.
    PubMed     Abstract available


    June 2016
  257. KIM MN, Park JY, Ahn SH, Kim BK, et al
    Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24616.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: